S&P 500   3,841.94
DOW   31,496.30
QQQ   306.41
S&P 500   3,841.94
DOW   31,496.30
QQQ   306.41
S&P 500   3,841.94
DOW   31,496.30
QQQ   306.41
S&P 500   3,841.94
DOW   31,496.30
QQQ   306.41
Log in

Enlivex Therapeutics Stock Forecast, Price & News

+0.41 (+3.16 %)
(As of 03/8/2021 08:45 AM ET)
Today's Range
Now: $13.40
50-Day Range
MA: $15.30
52-Week Range
Now: $13.40
Volume1,353 shs
Average Volume590,201 shs
Market Capitalization$211.18 million
P/E RatioN/A
Dividend YieldN/A
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Enlivex Therapeutics logo


Vandana Singh
February 3, 2021 |  benzinga.com
Enlivex Therapeutics Ltd
November 26, 2020 |  bloomberg.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ENLV
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$1.09 per share


Net Income$-9,380,000.00


Market Cap$211.18 million
Next Earnings Date4/29/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.38 out of 5 stars

Medical Sector

650th out of 1,968 stocks

Pharmaceutical Preparations Industry

312th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.41 (+3.16 %)
(As of 03/8/2021 08:45 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENLV News and Ratings via Email

Sign-up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Enlivex Therapeutics (NASDAQ:ENLV) Frequently Asked Questions

Is Enlivex Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Enlivex Therapeutics stock.
View analyst ratings for Enlivex Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Enlivex Therapeutics?

Wall Street analysts have given Enlivex Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Enlivex Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Enlivex Therapeutics?

Enlivex Therapeutics saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 57,900 shares, a decrease of 76.5% from the January 28th total of 246,900 shares. Based on an average daily volume of 509,400 shares, the short-interest ratio is presently 0.1 days. Approximately 0.7% of the company's shares are sold short.
View Enlivex Therapeutics' Short Interest

When is Enlivex Therapeutics' next earnings date?

Enlivex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Enlivex Therapeutics

How has Enlivex Therapeutics' stock been impacted by COVID-19?

Enlivex Therapeutics' stock was trading at $5.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ENLV shares have increased by 132.2% and is now trading at $13.40.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ENLV?

1 analysts have issued 1-year price objectives for Enlivex Therapeutics' stock. Their forecasts range from $33.00 to $33.00. On average, they anticipate Enlivex Therapeutics' stock price to reach $33.00 in the next twelve months. This suggests a possible upside of 146.3% from the stock's current price.
View analysts' price targets for Enlivex Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Enlivex Therapeutics' key executives?

Enlivex Therapeutics' management team includes the following people:
  • Mr. Shai Novik M.B.A., Exec. Chairman (Age 55, Pay $528k)
  • Dr. Oren Hershkovitz Ph.D., Chief Exec. Officer (Age 44, Pay $273.6k)
  • Prof. Dror Mevorach M.D., Founder and Chief Scientific & Medical Officer (Age 65, Pay $180k)
  • Ms. Shachar Shlosberger CPA, Chief Financial Officer (Age 44, Pay $126k)
  • Odelia Ben-Shitrit, Head of Clinical Operations
  • Dr. Danny Fishelovitch, Head of CMC

Who are some of Enlivex Therapeutics' key competitors?

What other stocks do shareholders of Enlivex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Enlivex Therapeutics' stock symbol?

Enlivex Therapeutics trades on the NASDAQ under the ticker symbol "ENLV."

Who are Enlivex Therapeutics' major shareholders?

Enlivex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.07%) and Golden Green Inc. (0.34%).

Which major investors are selling Enlivex Therapeutics stock?

ENLV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

Which major investors are buying Enlivex Therapeutics stock?

ENLV stock was purchased by a variety of institutional investors in the last quarter, including Golden Green Inc..

How do I buy shares of Enlivex Therapeutics?

Shares of ENLV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enlivex Therapeutics' stock price today?

One share of ENLV stock can currently be purchased for approximately $13.40.

How much money does Enlivex Therapeutics make?

Enlivex Therapeutics has a market capitalization of $211.18 million. The company earns $-9,380,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How many employees does Enlivex Therapeutics have?

Enlivex Therapeutics employs 36 workers across the globe.

What is Enlivex Therapeutics' official website?

The official website for Enlivex Therapeutics is www.enlivex.com.

Where are Enlivex Therapeutics' headquarters?

Enlivex Therapeutics is headquartered at 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042.

How can I contact Enlivex Therapeutics?

Enlivex Therapeutics' mailing address is 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042. The company can be reached via phone at 972-2620-8072 or via email at [email protected]

This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.